

Sean D. Sheridan
Vice President

PhD, Genetics
The University of Chicago

MBA, Finance and Economics
The University of Chicago
Booth School of Business

BS, Biology
Appalachian State University

Dr. Sheridan has served as an expert witness in cases brought before federal and state courts, the Patent Trial and Appeal Board, the International Trade Commission (ITC), and domestic and international arbitration tribunals. He has developed numerous damages analyses related to patent infringement, breach of contract, and trade secret misappropriation, including analyses quantifying lost profits, reasonable royalties, and unjust enrichment. He has also analyzed the issues of commercial success, irreparable harm, and the economic prong of the domestic industry requirement in ITC Section 337 proceedings. Outside of litigation, Dr. Sheridan has provided financial consulting services for purposes such as transaction due diligence, license negotiations, and strategic decision-making. The engagements he has worked on span a wide range of industries and products, including pharmaceuticals, biologics, medical devices, diagnostics, research tools, electronic health records, telecommunications, mobile devices, oil and gas, automotive technologies, computer software and hardware, insurance, and financial products, among others.

Previously, Dr. Sheridan was as an assistant director at the technology transfer office at the University of Chicago where he was responsible for managing the intellectual property strategy for a broad range of technologies and was frequently required to assess the value of new discoveries and potential products. In that role he personally negotiated a variety of contracts including licenses, option agreements, and collaboration agreements with companies ranging from Fortune 500 firms to small start-ups.

Dr. Sheridan is a frequent speaker and instructor on intellectual property valuation and publishes on related topics. He was named to the *IAM Patent 1000: The World's Leading Patent Professionals* (economic experts) every year since 2019.

Selected experience

Intellectual property consulting

- Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included a report and deposition testimony regarding certain liquid coolers.
- Developed economic analyses to determine whether there was evidence of commercial success for a Parkinson's disease psychosis treatment; deliverables included an initial report, reply report and deposition testimony on commercial success.

-
- Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included a report, deposition testimony and trial testimony regarding certain ice making machines.
 - Performed an assessment of the economic harm to a biologics manufacturer assuming biosimilar manufacturers launch at risk; deliverables included a declaration on irreparable harm and deposition testimony.
 - Performed an assessment of a pharmaceutical company's commercial launch plan and its sales and marketing efforts with respect to its "commercially reasonable efforts" obligations under a license agreement; deliverables included an expert report, deposition testimony and trial testimony.
 - Performed a domestic industry analysis and an analysis of the alleged threat of injury to a domestic industry in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an expert report, deposition testimony, and trial testimony regarding domestic investments in, and the alleged threat of injury to, certain botulinum toxin products.
 - Developed economic analyses to determine damages in a trade secret misappropriation case related to antibody discovery technology; deliverables included a report on counterclaim damages calculating lost profits, a rebuttal report calculating unjust enrichment and deposition testimony.
 - Provided opinions on technology transfer licensing practices; deliverables included an initial report and deposition testimony.
 - Provided opinions on various agreements involving technology transfer offices and typical technology transfer practices; deliverables included an initial report and deposition testimony.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included two declarations, a report, deposition testimony, and trial testimony regarding domestic investments in integrated circuit chips.
 - Developed economic analyses to determine whether there was evidence of commercial success for a Parkinson's disease psychosis treatment; deliverables included an initial report, reply report and deposition testimony on commercial success.
 - Developed economic analyses to determine whether there was evidence of commercial success for certain pre-operative skin sterilization products; deliverables included two reports on commercial success and deposition testimony.
 - Developed economic analyses to determine damages in a patent infringement case involving adjunctive stent technology; deliverables included an initial report on economic damages calculating reasonable royalties and deposition testimony.
 - Developed economic analyses to determine whether there was evidence of commercial success for a pharmaceutical product used for the treatment of psoriasis; deliverables included an initial report on commercial success and deposition testimony.

-
- Provided opinions on practices and procedures of technology transfer offices; deliverables included an initial report, deposition testimony and trial testimony.
 - Developed economic analyses relating to the interpretation of certain licensing provisions and the quantification of damages in a breach of contract case; deliverables included an initial report, deposition testimony and hearing testimony.
 - Developed economic analyses as a neutral advisor to the Tribunal in an international arbitration involving a licensing dispute relating to a novel rice herbicide candidate; deliverables included a flexible valuation model and report providing recommendations for license agreement terms and hearing testimony.
 - Developed economic analyses to determine damages in a breach of contract case related to the development of a vaccine product; deliverables included a report calculating actual loss damages, deposition testimony and hearing testimony.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial report, deposition testimony and hearing testimony regarding domestic investments in electrical connectors and cages.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial report, deposition testimony and hearing testimony regarding domestic investments in polycrystalline diamond compacts.
 - Developed economic analyses to determine damages in a patent infringement case involving crafting tools; deliverables included an initial report on economic damages calculating lost profits and reasonable royalties.
 - Developed economic analyses to determine an appropriate intercompany royalty rate to be paid for certain technological contributions to a comprehensive genomic profiling kit.
 - Developed economic analyses to determine damages in a breach of contract case related to therapeutic antibody products; deliverables included a report on economic damages calculating actual loss damages and unjust enrichment.
 - Developed economic analyses to determine whether there was evidence of commercial success for a pharmaceutical product used for the treatment of diabetes; deliverables included an initial report on commercial success.
 - Developed economic analyses to determine damages in a breach of contract and trade secret misappropriation case related to a propane dehydrogenation technology; deliverables included a report on economic damages calculating unjust enrichment.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial declaration regarding domestic investments in liquid crystal display devices.

-
- Performed a valuation analysis related to sustainable packaging technologies for consumer goods; deliverables included a flexible valuation model and a presentation for executive management.
 - Developed economic analyses to determine damages in a breach of contract case related to proprietary securities pricing data; deliverables included an initial report and reply report on economic damages calculating actual loss.
 - Developed economic analyses to determine damages in a breach of contract case related to the development of a cystic fibrosis therapy; deliverables included a report on economic damages calculating expectation damages.
 - Performed a valuation analysis related to a turbocharger patent portfolio; deliverables included a flexible valuation model and presentation.
 - Developed economic analyses to determine whether there was evidence of commercial success for certain medical procedure kits; deliverables included four reports on commercial success.
 - Developed economic analyses to determine whether there was evidence of commercial success for an antiparasitic medication; deliverables included an initial report on commercial success.
 - Developed economic analyses to determine damages in a patent infringement case involving catheter-related technology; deliverables included an initial report on economic damages calculating lost profits and reasonable royalties.
 - Developed economic analyses to determine whether there was evidence of commercial success for a pharmaceutical product used for the treatment of post-operative ileus; deliverables included an initial report on commercial success.
 - Developed economic analyses to determine damages in a trade secret misappropriation case related to reporting and accounting software used for portfolio management; deliverables included a report on economic damages calculating unjust enrichment.
 - Developed economic analyses to assist a biosimilar manufacturer in settlement negotiations with a competitor; deliverables included a flexible valuation model and decision tree analysis to address issues related to litigation risk, acceptable date of entry for the biosimilar product.
 - Developed economic analyses to determine damages in a trade secret misappropriation and breach of contract case related to cloud storage technology; deliverables included a report on economic damages calculating actual loss and unjust enrichment and deposition testimony.
 - Performed an assessment of the economic harm to a biologics manufacturer that could arise if a competitor was permitted to continue developing certain biosimilar products in the context of a trade secret case; deliverables included a report on irreparable harm.
 - Developed economic analyses to assist a pharmaceutical company in settlement negotiations with a potential generic competitor; deliverables included a flexible valuation model and decision tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.

-
- Performed a valuation analysis to assist a research hospital in determining the expected future licensing value of certain patents and the risk-adjusted settlement value related to an inventorship dispute involving a cancer immunotherapy technology.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial report regarding domestic investments in certain batteries and electrochemical device components and deposition and trial testimony.
 - Provided consulting expertise to assist a university with renegotiating a license agreement related to a gene-editing technology; deliverables included a flexible valuation model and a presentation for use in ongoing negotiations.
 - Developed economic analyses to determine whether there was evidence of commercial success for a pharmaceutical product used for the treatment of acne; deliverables included an initial report on commercial success.
 - Developed economic analyses to determine damages in a patent infringement case involving search engine technology; deliverables included an initial report on economic damages calculating reasonable royalties.
 - Developed economic analyses to determine damages in a breach of contract case related to microarray technology; deliverables included a preliminary damages report for settlement purposes, an initial report on economic damages and deposition testimony.
 - Developed economic analyses to determine damages in a patent infringement case involving transcatheter heart valve technology; deliverables included an initial report on economic damages calculating reasonable royalties.
 - Performed a valuation analysis related to packaging technology for consumer goods; deliverables included a flexible valuation model and a presentation for use in ongoing license negotiations.
 - Developed economic analyses to determine whether there was evidence of commercial success for a pharmaceutical product used for the treatment of pulmonary arterial hypertension; deliverables included an initial report on commercial success.
 - Developed economic analyses to assist a large telecommunications company in determining a reasonable licensing payment to settle ongoing litigation; deliverables included multiple decision tree analyses.
 - Developed economic analyses to determine damages in a patent infringement case involving smart home technology; deliverables included an initial report on economic damages calculating lost profits and reasonable royalties.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial report regarding domestic investments in certain hybrid electric vehicle components.

-
- Developed economic analyses to determine damages in a patent infringement case involving automotive multimedia systems; deliverables included an initial report on economic damages calculating reasonable royalties.
 - Developed economic analyses to determine damages in a patent infringement case involving a pharmaceutical product used for the treatment of congestive heart failure and skinny labeling by a generic competitor; deliverables included an initial report on economic damages calculating lost profits and reasonable royalties.
 - Developed economic analyses to determine damages in a breach of contract and patent infringement case involving orthopedic implants; deliverables included an initial report on economic damages calculating breach of contract damages and reasonable royalties. Prepared counsel for the deposition of the opposing expert on various topics.
 - Developed economic analyses to determine damages in a patent infringement case involving flash memory technology; deliverables included an initial report on economic damages calculating reasonable royalties. Prepared counsel for the deposition of the opposing expert on various topics.
 - Performed a valuation analysis related to orthopedic implant technology; deliverables included a flexible valuation model and a presentation for use in ongoing license negotiations.
 - Developed economic analyses to determine damages in a patent infringement case involving automotive safety technologies; deliverables included an initial report on economic damages calculating reasonable royalties.
 - Provided consulting expertise to assist a large insurance company with analyzing its IP management and licensing practices; deliverables included a comparison of the client's processes to industry best practices, specific recommendations to help align the client's IP and business strategies and, a detailed roadmap for achieving long-term IP goals.
 - Developed economic analyses to determine damages in a patent infringement case involving multiple telecommunication technologies; deliverables included an initial report on economic damages. Prepared counsel for the deposition of the opposing expert on various topics including reasonable royalties.
 - Performed a domestic industry analysis in the context of a Section 337 investigation conducted by the U.S. International Trade Commission; deliverables included an initial report and trial demonstratives regarding domestic investments in certain patented dental implant products.
 - Provided consulting expertise to assist an oil and gas company with strategic decision-making related to a subsidiary; deliverables included a patent landscape analysis and related market research.
 - Developed economic analyses used in a bankruptcy litigation case involving asset sale proceeds in excess of \$7.5B; deliverables included an initial report, rebuttal report, and trial demonstratives regarding the valuation of over 9,000 telecommunications patents and related license rights, as well as the inventive and financial contributions made by multiple debtor groups.

- Performed a valuation analysis in a patent malpractice dispute involving missed foreign patent application deadlines and other alleged patent prosecution errors. Provided pre-litigation analysis related to the risk adjusted present value of certain pending patent applications in Japan.
- Performed a valuation analysis in a patent infringement dispute involving electronic health records. Provided analysis related to the expected future value of multiple patent families in support of ongoing settlement negotiations.

Intellectual property transactions

- Negotiated and drafted a successfully executed exclusive patent license agreement with a multinational pharmaceutical company on behalf of a research university. The licensed patents related to a therapeutic protein scaffold technology.
- Negotiated and drafted a successfully executed exclusive patent license agreement with a large privately held biotechnology company on behalf of a research university. The licensed patents related to a protein immobilization technology with research and medical diagnostic applications.
- Negotiated and drafted a successfully executed exclusive patent license agreement with a start-up company on behalf of a research university. The licensed patents related to a biofuel production technology.
- Negotiated and drafted a successfully executed R&D collaboration agreement and a license option agreement with a start-up company on behalf of a research university. The subject of the R&D collaboration and the option agreement related to a peptide synthesis technology with therapeutic applications. The negotiated financial terms of the R&D collaboration included an equity stake in the start-up and funding for the research program.
- Negotiated and drafted a successfully executed exclusive patent license agreement with a start-up company on behalf of a research university. The licensed patents related to a medical diagnostic technology.
- Assisted a children's hospital in the negotiation and drafting of a successfully executed intellectual property management agreement with a research university. The negotiated financial terms included various cost-sharing and revenue-sharing structures.
- Assisted a coatings and paints manufacturer with its efforts to license or sell a patented 3D printing technology. Evaluated potential market applications, valued the technology in selected market applications, and created a flexible valuation model. Assisted in monetization strategy and term sheet negotiations with potential licensees.

Expert witness experience

- Certain Liquid Coolers for Electronic Components in Computers, Components Thereof, Devices for Controlling Same, and Products Containing Same
Cooler Master Co. Ltd. et al. v. SilverStone Technology Co., Ltd. et al.
U.S. International Trade Commission
Investigation No. 337-TA-1394.

Expert report and deposition testimony.

- Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Limited, et al.
Civil Action No. 1:22-cv-01387-GBW
United States District Court for the District of Delaware
Expert report, reply report, and deposition testimony.
- Certain Icemaking Machines and Components Thereof
Hoshizaki America Inc. v. Bluenix Co. Ltd., Blue Air FSE LLC.
U.S. International Trade Commission
Investigation No. 337-TA-1369
Expert report, deposition testimony and hearing testimony.
- Regeneron Pharmaceuticals, Inc. v. Amgen, Inc., Celltrion, Inc., Samsung Bioepis, Co., LTD., Formycon AG, and Mylan Pharmaceuticals, Inc.
Case Nos. 1:24-cv-00039-TSK, 1:23-cv-00089-TSK, 1:23-cv-00094-TSK, 1:23-cv-00097-TSK, 1:22-cv-00061-TSK
United States District Court for the Northern District of West Virginia
Declaration and deposition testimony.
- Consolidated Arbitration re: AltaThera Pharmaceuticals LLC, Hyloris Pharmaceuticals SA, Academic Pharmaceuticals Inc., and Dr. John Somberg
Case No. 01-22-0004-8710
American Arbitration Association
Expert report, deposition testimony and hearing testimony.
- Certain Botulinum Toxin Products and Processes for Manufacturing or Relating to Same
Medytox Inc. v. Hugel, Inc., et al.
U.S. International Trade Commission
Investigation No. 337-TA-1313
Expert report, deposition testimony and hearing testimony.

- Adimab, LLC v. LinkedUp Bioscience, Inc., et al.
Civil Action No. 2084CV00843 BLS2
Commonwealth of Massachusetts, Suffolk County Superior Court, Business Litigation Session
Initial expert report, rebuttal report and deposition testimony.
- Northwestern University v. Universal Robots A/S and Universal Robots USA, Inc.
Case No. 1:21-cv-00149-MN
United States District Court for the District of Delaware
Expert report and deposition testimony.
- University of Tennessee Research Foundation v. Caelum Biosciences, Inc., et al.
Case No. 3:19-cv-00508-CEA-HBG
United States District Court for the Eastern District of Tennessee at Knoxville
Expert report and deposition testimony.
- Certain Integrated Circuits, and Products Containing the Same Realtek Semiconductor Corporation v. Advanced Micro Devices, Inc.
U.S. International Trade Commission
Investigation No. 337-TA-1350
Two declarations, expert report, deposition testimony and hearing testimony.
- Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Limited, et al.
Civil Action No. 1:20-cv-00985-GBW
United States District Court for the District of Delaware
Initial expert report, reply report and deposition testimony.
- Becton Dickinson and Company v. Sage Products, LLC
Inter Partes Review Nos. IPR2021-01201 and IPR2021-01202
Patent Trial and Appeal Board
Two expert reports and deposition testimony.
- W.H. Wall Family Holdings, LLLP v. Stryker Corporation
Case No. 6:21-cv-00127-ADA
United States District Court for the Western District of Texas
Expert report and deposition testimony.
- The United States of America v. Gilead Sciences, Inc., et al.
Case No. 1:19-cv-02103-MN
United States District Court for the District of Delaware
Expert report.

-
- Bausch Health Ireland Ltd., et al. v. Padagis Israel Pharmaceuticals Ltd., et al.
Civil Action No. 2-20-cv-05426 (SRC) (CLW)
United States District Court for the District of New Jersey
Expert report, deposition testimony and trial testimony.
 - Gilead Sciences, Inc. v. The United States of America
Case No. 1:20-cv-00499-CFL
United States Court of Federal Claims
Expert report, deposition testimony and trial testimony.
 - Baxter International, Inc. and Baxter Healthcare Corp. v. CyDex Pharmaceuticals, Inc.
Case No. 01-21-0002-6106
American Arbitration Association
Initial expert report, rebuttal report, deposition testimony and hearing testimony.
 - Syngenta Crop Protection AG v. FMC Corp.
Case Nos. 01-19-0002-4208 and 01-19-0002-4192
American Arbitration Association, International Centre for Dispute Resolution
Expert report, flexible valuation model and hearing testimony.
 - Soligenix, Inc. v. Emergent BioSolutions, Inc., et al.
Case No. 01-20-0007-5817
American Arbitration Association
Expert report, deposition testimony and hearing testimony.
 - Certain Electrical Connectors and Cages, Components Thereof, and Products Containing the Same
Amphenol Corporation v. Luxshare Precision Industry Co., Ltd., et al.
U.S. International Trade Commission
Investigation No. 337-TA-1241
Expert report, deposition testimony and hearing testimony.
 - Certain Polycrystalline Diamond Compacts and Products Containing Same
US Synthetic Corporation v. CR Gems Superabrasives Co., Ltd., et al.
U.S. International Trade Commission
Investigation No. 337-TA-1236
Expert report, deposition testimony and hearing testimony.
 - My Sweet Petunia, Inc. v. Stampin' Up! Inc.
Case No. 2:18-CV-00796-CMR
United States District Court for the District of Utah
Expert report for mediation.
 - UOP, LLC and Nikki-Universal Co. Ltd. v. Hyosung Corporation
Case No. 2019Na2058149

Seoul High Court, South Korea
Expert report.

- Certain Liquid Crystal Display Devices, Components Thereof, and Products Containing Same Sharp Corporation and Sharp Electronics Corporation v. VIZIO, Inc. et al.
U.S. International Trade Commission
Investigation No. 337-TA-1201
Declaration.
- CR Bard, Inc. et al v. Medline Industries, Inc.
Inter Partes Review Nos. IPR2019-00035, IPR2019-00036, IPR2019-00109, IPR2019-00208 and IPR2019-00223
Patent Trial and Appeal Board
Four expert reports.
- Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals USA, Inc., and Taro Pharmaceutical Industries, Ltd.
Case No. 1:17-cv-09846-SHS
United States District Court for the Southern District of New York
Expert report.
- Falcon Group, LLC v. The Estate of Dennis Maetzold by and through its personal representative, David Logelin, and OCNA, L.L.C.
Civil Case No. 27-CV-17-15503
State of Minnesota – District Court, Hennepin County, Fourth Judicial District
Expert report and deposition testimony.
- Batteries and Electrochemical Devices Containing Composite Separators, Components Thereof, and Products Containing Same LG Chem, Ltd., et al. v. Amperex Technology Limited, et al.
U.S. International Trade Commission
Investigation No. 337-TA-1087
Expert report, deposition testimony and hearing testimony.
- Rutgers, The State University v. BioArray Solutions, Ltd., Immucor, Inc. and Michael Seul
Civil Action No. L-4747-14
Superior Court of New Jersey, Law Division, Middlesex County
Expert report and deposition testimony.

Publications and presentations

“Valuation as a Tool for Early-Stage Tech Transfer Agreements” Department of Energy, Technology Transfer Working Group, Webcast, 2024.

"Negotiating Successful Biopharma Partnerships" LES Annual Meeting, Chicago, IL, 2023, Moderator.

"Hot Topic: Pharmaceuticals and Biotechnology Patent Litigation," *Corporate Disputes Magazine*, Jan-Mar 2023 Issue, Co-author.

"Determining Royalty Rates for University IP: A Webinar Workshop for Tech Transfer and IP Professionals" Technology Transfer Tactics, Webcast, 2022.

"LES Life Sciences Global Royalty Rate Survey Report" Webcast, 2022, Co-presenter.

"LES@BIO 2022, Royalty Rates & Deal Terms Survey" BIO International Convention, San Diego, CA, 2022, Co-presenter.

"Biologically similar but competitively not so? Economic considerations of IP litigation settlements involving biosimilars" Podcast, *Our Curious Amalgam*, 2022, Guest.

"What's New for Hatch-Waxman Litigation: Exploring Trends, Updates, and Critical Issues" Webcast, The Knowledge Group, 2022, Co-presenter.

"IP Valuation and Licensing" Guest Lecture, University of Chicago Booth School of Business, Chicago, IL, 2022.

"FDA Biosimilar Approval Foreshadows IP Litigation Issues" With Archan Ruparel. *Law360*, 2021.

"Balancing Financial Risk in IP Licensing" Webcast, Washington State Bar Association, 2021.

"Intellectual Property Valuation" Guest Lecture, University of Chicago Booth School of Business, Chicago, IL, 2021.

"IP Valuation Basics" LES Course, Webcast, 2020, Co-instructor.

"Early Stage Intellectual Property Valuation" LES Course, Webcast, 2020, Co-instructor.

"Mini-Roundtable: Patent Disputes," *Corporate Disputes Magazine*, April-June 2020 Issue, Co-author.

"BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020" Webcast, The Knowledge Group, 2020, Co-presenter.

"Global Life Sciences Royalty Rate and Deal Terms Survey 2018" LES Annual Meeting, Phoenix, AZ, 2019, Co-presenter.

"Business Development for Life Sciences" LES Annual Meeting, Phoenix, AZ, 2019, Co-instructor.

"Apportionment and the Entire Fair Market Value Rule (EMVR) in Patent Damages: Trends, Methods and Best Practices in 2019" Webcast, The Knowledge Group, 2019, Co-presenter.

"Deal Terms - Do You Really Know What's Happening in Your Therapeutic Areas?" LES Webinar, 2019, Co-presenter.

"IP Valuation" LES University Course, Vancouver, BC, 2019, Co-instructor.

"Managing Risks and Uncertainty in Licensing Early-Stage Therapies" *Bloomberg Law*, 2018, Co-author.

“Navigating Implications for Reasonable Royalty Damages in Light of Exmark v. Briggs & Stratton and Other Recent Court Rulings” Webcast, The Knowledge Group, 2018, Co-presenter.

“Valuation and Negotiation” Polsky Center for Entrepreneurship and Innovation, Chicago, IL, 2017.

“Business Development for Life Sciences” LES University Course, Chicago, IL, 2017, Co-presenter.

“Global Life Sciences Royalty Rates and Deal Terms Survey, Implications and Applications” Webinar, 2017, Co-presenter.

“LES U.S.A. and Canada & LESI Global Life Sciences Royalty Rate and Deal Terms Survey 2016” Webinar, 2017, Co-presenter.

“Release of 5th Global Life Sciences Royalty Rate and Deal Terms Survey” LES 2016 Annual Meeting, Vancouver, BC, Canada, 2016, Co-presenter.

“Valuing IP” Guest Lecture, University of Notre Dame, Notre Dame, IN, 2016.

“Portfolio Analysis and Due Diligence for Monetization” IP Enforcement Summit, Chicago, IL, 2016, Co-presenter.

“How Mayo, Myriad and Alice May Impact Patent Valuations” *Law360*, 2015.

“Intellectual Property Valuation” Guest Lecture, University of Notre Dame, Notre Dame, IN, 2015.

CRA Insights: Intellectual Property, Editor, 2015 to 2021.

“Maximizing IP Value” Guest Lecture, Chicago-Kent College of Law, Chicago, IL, 2014.

“A chemical compound that stimulates the human homologous recombination protein RAD51.” With Krishanthi Jayathilaka, Tyler D Bold, Katarzyna Bochenska, Hillary L Logan, Ralph R. Weichselbaum, Douglas K. Bishop, and Philip P. Connell. *Proceedings of the National Academy of Sciences*, 2008.

“A comparative analysis of Dmc1 and Rad51 nucleoprotein filaments.” With Xiong Yu, Robyn Roth, John E. Heuser, Michael G. Sehorn, Patrick Sung, Edward H. Egelman, and Douglas K. Bishop. *Nucleic Acids Research*, 2008.

“Red Hed regulation: recombinase Rad51, though capable of playing the leading role, may be relegated to supporting Dmc1 in budding yeast meiosis.” With Douglas K. Bishop. *Genes & Development*, 2006.

Professional history

2023–Present	<i>Vice President</i> , Charles River Associates, Chicago, IL
2016–2023	<i>Principal</i> , Charles River Associates, Chicago, IL
2014–2016	<i>Associate Principal</i> , Charles River Associates, Chicago, IL
2014	<i>Director</i> , Ocean Tomo, Chicago, IL
2013–2014	<i>Associate</i> , Ocean Tomo, Chicago, IL
2012–2013	<i>Assistant Director</i> , UChicagoTech, Chicago, IL

2009–2012 *Project Manager*, UChicagoTech, Chicago, IL
2008–2009 *Associate Project Manager*, UChicagoTech, Chicago, IL
2001–2008 *Graduate Researcher*, The University of Chicago, Chicago, IL

Professional Affiliations

Licensing Executives Society, Member

American Intellectual Property Law Association, Member

Association of University Technology Managers, Member